A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

NCT04271475 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
127
Enrollment
INDUSTRY
Sponsor class

Stopped The Sponsor decided to stop the study for futility based on a recommendation by the IDMC following a pre-planned interim analysis

Conditions

Interventions

Sponsor

Actelion